Your browser is no longer supported. Please, upgrade your browser.
BCEL Atreca, Inc. weekly Stock Chart
Atreca, Inc.
Index- P/E- EPS (ttm)-2.19 Insider Own6.87% Shs Outstand20.79M Perf Week1.57%
Market Cap308.52M Forward P/E- EPS next Y-2.60 Insider Trans0.00% Shs Float14.58M Perf Month0.95%
Income-59.40M PEG- EPS next Q-0.64 Inst Own86.10% Short Float7.21% Perf Quarter38.56%
Sales- P/S- EPS this Y-37.80% Inst Trans-0.06% Short Ratio8.06 Perf Half Y-7.31%
Book/sh7.33 P/B2.02 EPS next Y31.40% ROA- Target Price28.20 Perf Year-
Cash/sh9.67 P/C1.53 EPS next 5Y- ROE- 52W Range9.51 - 23.65 Perf YTD-4.07%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.31% Beta-
Dividend %- Quick Ratio27.40 Sales past 5Y- Gross Margin- 52W Low58.40% ATR1.69
Employees102 Current Ratio27.40 Sales Q/Q- Oper. Margin- RSI (14)53.49 Volatility7.77% 12.48%
OptionableNo Debt/Eq0.00 EPS Q/Q-57.80% Profit Margin- Rel Volume0.35 Prev Close14.84
ShortableYes LT Debt/Eq0.00 EarningsNov 12 Payout- Avg Volume130.46K Price15.06
Recom1.70 SMA20-0.70% SMA5013.24% SMA2008.18% Volume15,477 Change1.51%
Sep-04-19Initiated ROTH Capital Buy $30
Jul-15-19Initiated Stifel Buy $28
Jul-15-19Initiated Evercore ISI Outperform
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated Canaccord Genuity Buy $23
Dec-26-19 10:48AM  These new Bay Area stocks from 2019 are 'underwater' as year ends American City Business Journals +16.91%
Dec-19-19 04:54PM  Hedge Funds Staying Clear Of Atreca, Inc. (NASDAQ:BCEL) Insider Monkey -9.02%
Dec-03-19 08:00AM  Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101 GlobeNewswire +32.34%
Nov-14-19 08:00AM  Atreca to Present at Two Upcoming Investor Conferences GlobeNewswire
Nov-12-19 04:05PM  Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Nov-05-19 08:00AM  Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Sep-19-19 09:19AM  Do Institutions Own Shares In Atreca, Inc. (NASDAQ:BCEL)? Simply Wall St.
Aug-26-19 04:05PM  Atreca Announces Appointment of Dr. Lindsey Rolfe to its Board of Directors GlobeNewswire -6.49%
Aug-17-19 07:30AM  Stanford University Now Owns Stakes in Uber and Pinterest Stock
Aug-13-19 04:05PM  Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire +25.78%
Jul-15-19 02:22PM  Stifel: Atreca Offers Attractive Oncology Drug Development Play Benzinga
Jul-11-19 08:00AM  Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel GlobeNewswire
Jun-20-19 11:16AM  Atreca Opens For Trade Benzinga
Jun-19-19 09:40PM  Atreca Announces Pricing of Initial Public Offering GlobeNewswire
08:20AM  Atreca IPO: What You Need To Know Benzinga
Jun-17-19 10:07AM  IPO Outlook For The Week: Biotechs And A Grocery Outlet Benzinga
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a research collaboration agreement with Serimmune, which applies serum epitope repertoire analysis platform that maps the antigenic targets of antibody repertoires to identify the targets of selected therapeutic antibody candidates for oncology generated by the company. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.